Minerva Neurosciences, Inc. (NERV)
| Market Cap | 257.79M +2,013.0% |
| Revenue (ttm) | n/a |
| Net Income | -415.07M |
| EPS | -23.66 |
| Shares Out | 43.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,679 |
| Open | 6.10 |
| Previous Close | 6.13 |
| Day's Range | 5.86 - 6.10 |
| 52-Week Range | 1.30 - 12.46 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 10.50 (+77.52%) |
| Earnings Date | May 5, 2026 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NERV stock is "Buy." The 12-month stock price target is $10.5, which is an increase of 77.52% from the latest price.
News
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–dr...
Minerva initiated with an Outperform at Citizens
Citizens initiated coverage of Minerva (NERV) with an Outperform rating and $14 price target Minerva is developing roluperidone for the treatment of negative symptoms of schizophrenia, the analyst tel...
Minerva appoints Jim O’Connor as chief business officer
Minerva (NERV) announced a leadership transition with the appointment of Jim O’Connor as chief business officer, effective April 21, as Geoff Race, the company’s president, has elected to leave the
Minerva Announces Leadership Transition
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva screens first patient in roluperidone trial
Minerva (NERV) announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of sc...
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2...
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data...
Minerva Neurosciences Transcript: Stifel 2026 Virtual CNS Forum
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise as a monotherapy that improves both symptoms and functioning without typical antipsychotic side effects. The pivotal trial is underway, with top-line results expected in the second half of next year.
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva price target raised to $7 from $4 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Minerva (NERV) to $7 from $4 and keeps a Neutral rating on the shares. The firm cites the “promising positioning” of the
Minerva files $200M mixed securities shelf
09:23 EDT Minerva (NERV) files $200M mixed securities shelf
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 Initiation of confirmatory Phase 3 tr...
Minerva Neurosciences Transcript: The Citizens Life Sciences Conference 2026
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise in improving both symptoms and daily functioning. The ongoing confirmatory phase III trial, supported by strong FDA engagement and $200 million in financing, aims to validate these results and enable U.S. launch.
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva Neurosciences Transcript: KOL event
The event detailed the clinical and regulatory progress of roluperidone for negative symptoms in schizophrenia, highlighting robust efficacy, low relapse rates, and a strategic phase III trial design. Experts emphasized the drug's unique mechanism and potential for broader indications, with strong investor and FDA support.
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva files to sell 94.6M shares of common stock for holders
16:08 EST Minerva (NERV) files to sell 94.6M shares of common stock for holders
Minerva price target raised to $5 from $3 at Jefferies
Jefferies raised the firm’s price target on Minerva (NERV) to $5 from $3 and keeps a Hold rating on the shares. Oral roluperidone has the potential to benefit the negative
Minerva appoints Kaul to board of directors
Minerva (NERV) Neurosciences, announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
Minerva price target lowered to $4 from $5 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Minerva (NERV) to $4 from $5 and keeps a Neutral rating on the shares. The firm cites equity dilution for the target
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical...
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...